BioPharma Credit Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Other Revenue	157.75	150.03	135.74	218.17	103.88
Revenue	157.75	150.03	135.74	218.17	103.88
Revenue Growth (YoY)	5.14%	10.53%	-37.78%	110.02%	-5.58%
Gross Profit	157.75	150.03	135.74	218.17	103.88
Selling, General & Admin	28.03	27.72	27.28	35.79	18.95
Other Operating Expenses	-0.14	0.13	0	0.04	-0.05
Operating Expenses	27.9	27.85	27.28	35.83	18.9
Operating Income	129.85	122.18	108.46	182.34	84.98
Currency Exchange Gain (Loss)	0.04	-0	-0.01	-0.03	-0.02
Pretax Income	129.89	122.18	108.45	182.31	84.96
Net Income	129.89	122.18	108.45	182.31	84.96
Net Income to Common	129.89	122.18	108.45	182.31	84.96
Net Income Growth	6.31%	12.66%	-40.51%	114.59%	-4.69%
Shares Outstanding (Basic)	1,140	1,222	1,309	1,364	1,374
Shares Outstanding (Diluted)	1,140	1,222	1,309	1,364	1,374
Shares Change (YoY)	-6.77%	-6.65%	-4.00%	-0.72%	-0.00%
EPS (Basic)	0.11	0.10	0.08	0.13	0.06
EPS (Diluted)	0.11	0.10	0.08	0.13	0.06
EPS Growth	14.03%	20.68%	-38.03%	116.14%	-4.68%
Dividend Per Share	0.070	0.070	0.070	0.070	0.070
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	82.31%	81.44%	79.90%	83.58%	81.80%
Profit Margin	82.34%	81.44%	79.90%	83.56%	81.79%
EBIT	129.85	122.18	108.46	182.34	84.98
EBIT Margin	82.31%	81.44%	79.90%	83.58%	81.80%
Revenue as Reported	157.78	150.03	135.73	218.14	103.86